Mdma molecule:

Image from PubChem

Mdma Clinical Trials

An adaptive Phase II/III, Double-Blind, Randomized, Placebo-controlled, Two-Part, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen® (sodium benzoate), a D-Amino Acid Oxidase Inhibitor, as an Add-on with Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults

To see complete record on, please visit this link

Id: 2017-001170-42

Organisation Name: SyneuRx International (Taiwan) Corp

Start Date: 2019-05-10

Completion Date: Ongoing

Brief Summary: The 2 primary objectives for Part 1 of this study are:

Country: United States

Total execution time in seconds: 0.092648983001709